Preoperative systemic immune-inflammation index predicts prognosis of patients with non-metastatic renal cell carcinoma: a propensity score-matched analysis

Hu, Xu; Shao, Yabin; Yang, Zhiqiang; Dou, Wei-Chao; Xiong, San-Chao; Li, Xiang

doi:10.1186/s12935-020-01320-w

Cited by 29 publications

(30 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The association between and SII was also reported in other solid tumors [23,32]. For example, Hu et al analyzed 646 non-metastatic renal cell carcinoma patients treated with nephrectomy and found high SII (> 529) as an independent predictor of CSS (HR = 2.17, 95% CI 1.33-3.55, p = 0.002) and OS (HR = 2.26, 95% CI 1.44-3.54, p < 0.001) [32]. Also, in a recent meta-analysis of eight studies, Zhang et al determined high SII as a prognostic factor for worse OS (HR = 1.79, 95% CI 1.33-2.42, p < 0.001) in breast cancer patients [23].…”

Section: Discussionsupporting

confidence: 70%

“…This is contradictory to the recent study of Stangl-Kremser et al who did not find a significant association between SII > 200 and overall survival in the CRPC cohort treated with docetaxel (HR 1.0, 95% CI 0.9-1.0, p = 0.06) [21]. The association between and SII was also reported in other solid tumors [23,32]. For example, Hu et al analyzed 646 non-metastatic renal cell carcinoma patients treated with nephrectomy and found high SII (> 529) as an independent predictor of CSS (HR = 2.17, 95% CI 1.33-3.55, p = 0.002) and OS (HR = 2.26, 95% CI 1.44-3.54, p < 0.001) [32].…”

Section: Discussionmentioning

confidence: 65%

See 1 more Smart Citation

Role of systemic immune-inflammation index in patients treated with salvage radical prostatectomy

et al. 2021

View full text Add to dashboard Cite

Purpose To examine the predictive and prognostic value of preoperative Systemic Immune-inflammation Index (SII) in patients with radio-recurrent prostate cancer (PCa) treated with salvage radical prostatectomy (SRP). Materials and methods This multicenter retrospective study included 214 patients with radio-recurrent PCa, treated with SRP between 2007 and 2015. SII was measured preoperatively (neutrophils × platelets/lymphocytes) and the cohort was stratified using optimal cut-off. Uni- and multivariable logistic and Cox regression analyses were performed to evaluate the predictive and prognostic value of SII as a preoperative biomarker. Results A total of 81 patients had high preoperative SII (≥ 730). On multivariable logistic regression modeling, high SII was predictive for lymph node metastases (OR 3.32, 95% CI 1.45–7.90, p = 0.005), and non-organ confined disease (OR 2.55, 95% CI 1.33–4.97, p = 0.005). In preoperative regression analysis, high preoperative SII was an independent prognostic factor for cancer-specific survival (CSS; HR 10.7, 95% CI 1.12–103, p = 0.039) and overall survival (OS; HR 8.57, 95% CI 2.70–27.2, p < 0.001). Similarly, in postoperative multivariable models, SII was associated with worse CSS (HR 22.11, 95% CI 1.23–398.12, p = 0.036) and OS (HR 5.98, 95% CI 1.67–21.44, p = 0.006). Notably, the addition of SII to preoperative reference models improved the C-index for the prognosis of CSS (89.5 vs. 80.5) and OS (85.1 vs 77.1). Conclusions In radio-recurrent PCa patients, high SII was associated with adverse pathological features at SRP and survival after SRP. Preoperative SII could help identify patients who might benefit from novel imaging modalities, multimodal therapy or a closer posttreatment surveillance.

show abstract

Section: Discussionsupporting

confidence: 70%

Section: Discussionmentioning

confidence: 65%

Role of systemic immune-inflammation index in patients treated with salvage radical prostatectomy

et al. 2021

View full text Add to dashboard Cite

show abstract

“…The included studies were published from 2016 to 2020, with a sample size between 70 and 646 and a cut-off value of SII between 200 and 1375. Of them, six studies assessed the relationship between SII and prognosis in renal cell carcinoma (RCC) patients, [19,[22][23][24][25][26] two investigated upper tract urothelial carcinoma (UTUC), [20,27] two focused on bladder cancer (BC), [28,29] and three explored PC. [18,30,31] In terms of the research quality evaluation, the NOS score was 9 for three datasets, 8 for six datasets, 7 for one dataset, and 6 for ve datasets, demonstrating that the included articles were overall of high quality.…”

Section: Search Results and Study Characteristicsmentioning

confidence: 99%

Systemic Immune-Inflammation Index is a Promising Noninvasive Biomarker for Predicting the Survival of Urinary System Cancers: A Systematic Review and Meta-Analysis

Chen

et al. 2021

Preprint

View full text Add to dashboard Cite

Purpose: Systemic immune-inflammation index (SII) has been reported in numerous studies to effectively predict the pathological features and survival outcomes of urinary system cancers, but no agreement has been reached. The aim of this meta-analysis is to explore the prognostic significance of pretreatment SII in tumours of the urinary system.Methods: Relevant published articles were selected from Web of Science, PubMed, Embase, and the Cochrane Library up to August 30, 2020. The pooled hazard ratios (HRs), odds ratios (ORs), and standard mean differences (SMDs) with 95% confidence intervals (CIs) were computed to estimate the associations of pretreatment SII with overall survival (OS), progression-free survival (PFS), cancer-specific survival (CSS), and clinicopathological parameters in urinary system cancers.Results: Overall, a total of 13 papers published from 2016 to 2020 involving 15 datasets comprising 3974 patients were finally included in our meta-analysis. From the combined data, we found that high SII prior to treatment indicated markedly worse OS (HR =1.98, 95% CI: 1.75–2.23; p < 0.001), PFS (HR: 2.08, 95% CI: 1.32–3.26, p = 0.002) with high heterogeneity (I2 = 80.8%, p < 0.001), and CSS (HR: 2.41, 95% CI: 1.73–3.35, p < 0.001). In addition, patients who have an elevated SII value before receiving treatment might have undesirable pathological characteristics, including large tumour size, poor differentiation grade, and advanced tumour stage (all p < 0.001).Conclusion: Pretreatment SII could be used as a noninvasive and promising biomarker for indicating the prognosis of patients with urinary system cancers.

show abstract

“…Recently, there have been many inflammation-based prognostic biomarkers which constructed on systemic inflammatory responses, such as the Glasgow Prognostic Score (GPS) and modified Glasgow Prognostic Score (mGPS), Prognostic Index (PI), Prognostic Nutritional Index (PNI), neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR), lymphocyte to monocyte ratio (LMR), and systemic immune-inflammation index (SII). These biomarkers have shown prognostic value in several types of cancer, including lung cancer, 9 , 10 biliary tract cancer, 11 renal cell carcinoma, 12 esophageal cancer, 13 and CRC. 14 Our previous study illustrated that preoperative fibrinogen (Fib) to pre-albumin (pre-Alb) ratio (FPR) was tightly associated with chemotherapy response and the outcome of advanced CRC.…”

Section: Introductionmentioning

confidence: 99%

“…Continuous variables were described as the median and quartile, and they were compared by Kolmogorov-Smirnov and Mann-Whitney U-test. Kaplan-Meier curve with a Log rank test was selected to 12 1 dNLR (WBC-neutrophil)/lymphocyte≤2.30 0 (WBC-neutrophil)/lymphocyte>2. 30 1…”

mentioning

confidence: 99%

The Role of Cancer-Elicited Inflammatory Biomarkers in Predicting Early Recurrence Within Stage II–III Colorectal Cancer Patients After Curable Resection

Ying¹,

Liao²,

Sun³

et al. 2021

JIR

View full text Add to dashboard Cite

Background: Smoldering cancer-related inflammation attenuates chemotherapy efficacy and contributes to unsatisfactory outcome for patients of colorectal cancer (CRC). Various inflammation-based biomarkers were reported to predict the survival of the disease, however, it remains unclear which is the best inflammation-based biomarker. The aim of present study was to compare the prognostic role of those biomarkers and to establish superior survival score for post-recurrence survival in radically operative patients with stage II-III CRC. Patients and Methods: Preoperative peripheral neutrophil, lymphocyte, monocyte, platelet, serum albumin (Alb), pre-Alb, and plasma fibrinogen (Fib) were detected in the discovery and validation cohort which included a total of 1533 stage II-III surgical CRC patients. We calculated and compared fourteen inflammation-based biomarkers for predicting recurrence-free survival (RFS) of the patients with stage II-III CRC. Results: In this study, the platelet to lymphocyte ratio (PLR), lymphocyte to monocyte (LMR), systemic inflammation response index (SIRI), prognostic nutritional index (PNI), systemic immune-inflammation index (SII), modified systemic inflammation score (mSIS), fibrinogen and neutrophil to lymphocyte ratio score (F-NLR), ratio of Alb to Fib (AFR), and ratio of Fib to pre-Alb (FPR) were all related to the RFS of the patients in both discovery and validation cohorts, however, only the LMR, SIRI, PNI, mSIS, F-NLR, AFR and FPR remained independent predictors for RFS in multivariate analysis. Both the C-index of the FPR (0.629 for 36 months) and the areas under the time-dependent receiver operating characteristic (ROC) curves (0.625 for 12 months, 0.641 for both 24 and 0.637 months) showed that it was superior to the other inflammation-based prognostic scores for predicting the RFS of stage II-III surgical CRC patients. Moreover, elevated FPR was significantly associated with unsatisfactory RFS regardless of TNM stage and primary tumor location. Stage II low FPR patients showed the best RFS regardless of chemotherapy. The better RFS was observed in chemotherapy-treated stage II high FPR patients than those without the treatment, and the outcomes of patients with treatment of XELOX, capecitabine and XELOX were superior to the other regimens to treat patients in stage III low-and high-FPR populations, respectively. Additionally, the carcinoembryonic antigen (CEA)-FPR combined score one (adjusted HR=2.764, 95% CI=2.129-3.589) and two (adjusted HR=3.543, 95% CI=2.317-5.420) were extremely associated with RFS of these patients, and the predicted AUC of the combined score for 12, 24 and 36 months were 0.657, 0.657 and 0.653 in stage II-III patients, which were superior to the single CEA and FPR, respectively. Conclusion:In conclusion, FPR is superior to the other inflammatory biomarkers as a useful recurrence indicator in stage II-III surgical CRC patients in terms of prognostic

show abstract

Preoperative systemic immune-inflammation index predicts prognosis of patients with non-metastatic renal cell carcinoma: a propensity score-matched analysis

Cited by 29 publications

References 38 publications

Role of systemic immune-inflammation index in patients treated with salvage radical prostatectomy

Role of systemic immune-inflammation index in patients treated with salvage radical prostatectomy

Systemic Immune-Inflammation Index is a Promising Noninvasive Biomarker for Predicting the Survival of Urinary System Cancers: A Systematic Review and Meta-Analysis

The Role of Cancer-Elicited Inflammatory Biomarkers in Predicting Early Recurrence Within Stage II–III Colorectal Cancer Patients After Curable Resection

Contact Info

Product

Resources

About